Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.

Identifieur interne : 000B75 ( Main/Exploration ); précédent : 000B74; suivant : 000B76

Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.

Auteurs : Courtney M. Daczkowski [États-Unis] ; Octavia Y. Goodwin [États-Unis] ; John V. Dzimianski [États-Unis] ; Jonathan J. Farhat [États-Unis] ; Scott D. Pegan [États-Unis]

Source :

RBID : pubmed:28931677

Descripteurs français

English descriptors

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that is the causative agent for Middle East respiratory syndrome (MERS). With MERS outbreaks resulting in over 35% fatalities and now spread to 27 countries, MERS-CoV poses a significant ongoing threat to global human health. As part of its viral genome, MERS-CoV encodes a papain-like protease (PLpro) that has been observed to act as a deubiquitinase and deISGylase to antagonize type I interferon (IFN-I) immune pathways. This activity is in addition to its viral polypeptide cleavage function. Although the overall impact of MERS-CoV PLpro function is observed to be essential, difficulty has been encountered in delineating the importance of its separate functions, particularly its deISGylase activity. As a result, the interface of MERS-CoV and human interferon-stimulated gene product 15 (hISG15) was probed with isothermal calorimetry, which suggests that the C-terminal domain of hISG15 is principally responsible for interactions. Subsequently, the structure of MERS-CoV PLpro was solved to 2.4 Å in complex with the C-terminal domain of hISG15. Utilizing this structural information, mutants were generated that lacked appreciable deISGylase activity but retained wild-type deubiquitinase and peptide cleavage activities. Hence, this provides a new platform for understanding viral deISGylase activity within MERS-CoV and other CoVs.IMPORTANCE Coronaviruses, such as Middle East respiratory syndrome coronavirus (MERS-CoV), encode a papain-like protease (PLpro) that possesses the ability to antagonize interferon immune pathways through the removal of ubiquitin and interferon-stimulated gene product 15 (ISG15) from target proteins. The lack of CoV proteases with attenuated deISGylase activity has been a key obstacle in delineating the impact between deubiquitinase and deISGylase activities on viral host evasion and pathogenesis. Here, biophysical techniques revealed that MERS-CoV PLpro chiefly engages human ISG15 through its C-terminal domain. The first structure of MERS-CoV PLpro in complex with this domain exposed the interface between these two entities. Employing these structural insights, mutations were employed to selectively remove deISGylase activity with no appreciable impact on its other deubiquitinase and peptide cleavage biochemical properties. Excitingly, this study introduces a new tool to probe the pathogenesis of MERS-CoV and related viruses through the removal of viral deISGylase activity.

DOI: 10.1128/JVI.01067-17
PubMed: 28931677


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.</title>
<author>
<name sortKey="Daczkowski, Courtney M" sort="Daczkowski, Courtney M" uniqKey="Daczkowski C" first="Courtney M" last="Daczkowski">Courtney M. Daczkowski</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goodwin, Octavia Y" sort="Goodwin, Octavia Y" uniqKey="Goodwin O" first="Octavia Y" last="Goodwin">Octavia Y. Goodwin</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dzimianski, John V" sort="Dzimianski, John V" uniqKey="Dzimianski J" first="John V" last="Dzimianski">John V. Dzimianski</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Farhat, Jonathan J" sort="Farhat, Jonathan J" uniqKey="Farhat J" first="Jonathan J" last="Farhat">Jonathan J. Farhat</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Pegan, Scott D" sort="Pegan, Scott D" uniqKey="Pegan S" first="Scott D" last="Pegan">Scott D. Pegan</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA spegan@uga.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28931677</idno>
<idno type="pmid">28931677</idno>
<idno type="doi">10.1128/JVI.01067-17</idno>
<idno type="wicri:Area/PubMed/Corpus">000B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B45</idno>
<idno type="wicri:Area/PubMed/Curation">000B45</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B45</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000B15</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B15</idno>
<idno type="wicri:Area/Ncbi/Merge">001B87</idno>
<idno type="wicri:Area/Ncbi/Curation">001B87</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B87</idno>
<idno type="wicri:Area/Main/Merge">000B78</idno>
<idno type="wicri:Area/Main/Curation">000B75</idno>
<idno type="wicri:Area/Main/Exploration">000B75</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.</title>
<author>
<name sortKey="Daczkowski, Courtney M" sort="Daczkowski, Courtney M" uniqKey="Daczkowski C" first="Courtney M" last="Daczkowski">Courtney M. Daczkowski</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Goodwin, Octavia Y" sort="Goodwin, Octavia Y" uniqKey="Goodwin O" first="Octavia Y" last="Goodwin">Octavia Y. Goodwin</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Dzimianski, John V" sort="Dzimianski, John V" uniqKey="Dzimianski J" first="John V" last="Dzimianski">John V. Dzimianski</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Farhat, Jonathan J" sort="Farhat, Jonathan J" uniqKey="Farhat J" first="Jonathan J" last="Farhat">Jonathan J. Farhat</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Pegan, Scott D" sort="Pegan, Scott D" uniqKey="Pegan S" first="Scott D" last="Pegan">Scott D. Pegan</name>
<affiliation wicri:level="2">
<nlm:affiliation>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia, USA spegan@uga.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>Pharmaceutical and Biomedical Sciences Department, University of Georgia, Athens, Georgia</wicri:regionArea>
<placeName>
<region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint>
<date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Calorimetry</term>
<term>Crystallography, X-Ray</term>
<term>Cysteine Endopeptidases (chemistry)</term>
<term>Cysteine Endopeptidases (metabolism)</term>
<term>Cytokines (chemistry)</term>
<term>Cytokines (metabolism)</term>
<term>Deubiquitinating Enzymes (metabolism)</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Interferons (antagonists & inhibitors)</term>
<term>Middle East Respiratory Syndrome Coronavirus (enzymology)</term>
<term>Middle East Respiratory Syndrome Coronavirus (genetics)</term>
<term>Middle East Respiratory Syndrome Coronavirus (metabolism)</term>
<term>Middle East Respiratory Syndrome Coronavirus (pathogenicity)</term>
<term>Mutation</term>
<term>Ubiquitin (metabolism)</term>
<term>Ubiquitins (chemistry)</term>
<term>Ubiquitins (metabolism)</term>
<term>Viral Proteins (chemistry)</term>
<term>Viral Proteins (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Calorimétrie</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (enzymologie)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (métabolisme)</term>
<term>Coronavirus du syndrome respiratoire du Moyen-Orient (pathogénicité)</term>
<term>Cristallographie aux rayons X</term>
<term>Cysteine endopeptidases ()</term>
<term>Cysteine endopeptidases (métabolisme)</term>
<term>Cytokines ()</term>
<term>Cytokines (métabolisme)</term>
<term>Enzymes de désubiquitinylation (métabolisme)</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Interférons (antagonistes et inhibiteurs)</term>
<term>Mutation</term>
<term>Protéines virales ()</term>
<term>Protéines virales (métabolisme)</term>
<term>Ubiquitine (métabolisme)</term>
<term>Ubiquitines ()</term>
<term>Ubiquitines (métabolisme)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Interferons</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en">
<term>Cysteine Endopeptidases</term>
<term>Cytokines</term>
<term>Ubiquitins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Cysteine Endopeptidases</term>
<term>Cytokines</term>
<term>Deubiquitinating Enzymes</term>
<term>Ubiquitin</term>
<term>Ubiquitins</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Interférons</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr">
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
<term>Cysteine endopeptidases</term>
<term>Cytokines</term>
<term>Enzymes de désubiquitinylation</term>
<term>Protéines virales</term>
<term>Ubiquitine</term>
<term>Ubiquitines</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en">
<term>Middle East Respiratory Syndrome Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr">
<term>Coronavirus du syndrome respiratoire du Moyen-Orient</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Calorimetry</term>
<term>Crystallography, X-Ray</term>
<term>Host-Pathogen Interactions</term>
<term>Humans</term>
<term>Mutation</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Calorimétrie</term>
<term>Cristallographie aux rayons X</term>
<term>Cysteine endopeptidases</term>
<term>Cytokines</term>
<term>Humains</term>
<term>Interactions hôte-pathogène</term>
<term>Mutation</term>
<term>Protéines virales</term>
<term>Ubiquitines</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging human pathogen that is the causative agent for Middle East respiratory syndrome (MERS). With MERS outbreaks resulting in over 35% fatalities and now spread to 27 countries, MERS-CoV poses a significant ongoing threat to global human health. As part of its viral genome, MERS-CoV encodes a papain-like protease (PLpro) that has been observed to act as a deubiquitinase and deISGylase to antagonize type I interferon (IFN-I) immune pathways. This activity is in addition to its viral polypeptide cleavage function. Although the overall impact of MERS-CoV PLpro function is observed to be essential, difficulty has been encountered in delineating the importance of its separate functions, particularly its deISGylase activity. As a result, the interface of MERS-CoV and human interferon-stimulated gene product 15 (hISG15) was probed with isothermal calorimetry, which suggests that the C-terminal domain of hISG15 is principally responsible for interactions. Subsequently, the structure of MERS-CoV PLpro was solved to 2.4 Å in complex with the C-terminal domain of hISG15. Utilizing this structural information, mutants were generated that lacked appreciable deISGylase activity but retained wild-type deubiquitinase and peptide cleavage activities. Hence, this provides a new platform for understanding viral deISGylase activity within MERS-CoV and other CoVs.
<b>IMPORTANCE</b>
Coronaviruses, such as Middle East respiratory syndrome coronavirus (MERS-CoV), encode a papain-like protease (PLpro) that possesses the ability to antagonize interferon immune pathways through the removal of ubiquitin and interferon-stimulated gene product 15 (ISG15) from target proteins. The lack of CoV proteases with attenuated deISGylase activity has been a key obstacle in delineating the impact between deubiquitinase and deISGylase activities on viral host evasion and pathogenesis. Here, biophysical techniques revealed that MERS-CoV PLpro chiefly engages human ISG15 through its C-terminal domain. The first structure of MERS-CoV PLpro in complex with this domain exposed the interface between these two entities. Employing these structural insights, mutations were employed to selectively remove deISGylase activity with no appreciable impact on its other deubiquitinase and peptide cleavage biochemical properties. Excitingly, this study introduces a new tool to probe the pathogenesis of MERS-CoV and related viruses through the removal of viral deISGylase activity.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Géorgie (États-Unis)</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Géorgie (États-Unis)">
<name sortKey="Daczkowski, Courtney M" sort="Daczkowski, Courtney M" uniqKey="Daczkowski C" first="Courtney M" last="Daczkowski">Courtney M. Daczkowski</name>
</region>
<name sortKey="Dzimianski, John V" sort="Dzimianski, John V" uniqKey="Dzimianski J" first="John V" last="Dzimianski">John V. Dzimianski</name>
<name sortKey="Farhat, Jonathan J" sort="Farhat, Jonathan J" uniqKey="Farhat J" first="Jonathan J" last="Farhat">Jonathan J. Farhat</name>
<name sortKey="Goodwin, Octavia Y" sort="Goodwin, Octavia Y" uniqKey="Goodwin O" first="Octavia Y" last="Goodwin">Octavia Y. Goodwin</name>
<name sortKey="Pegan, Scott D" sort="Pegan, Scott D" uniqKey="Pegan S" first="Scott D" last="Pegan">Scott D. Pegan</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B75 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B75 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28931677
   |texte=   Structurally Guided Removal of DeISGylase Biochemical Activity from Papain-Like Protease Originating from Middle East Respiratory Syndrome Coronavirus.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28931677" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021